Journal of Asthma, 20(6), 487–488 (1983)

AUTHOR INDEX

VOLUME 20

B

Baskerville, J., S51–S60
Bieman, C.W., 383–389
Bierman, C.W., 435–444
Bock, S.A., 335–339, 377–381
Bostrom, A., 27–30
Brandon, M.L., 105–113
Brown, G.L., 133–151
Bukantz, S.C., 177–181
Burns, K., 183–188
Burns, R.B.P., 105–113
Busse, W.W., 85–91

C

Cea-Gil, F., 93–96
Chryssanthopoulos, C., 35–38, 285–296
Coifman, R.E., 45–52
Creer, P.P., 11–15, 97–104
Creer, T.L., 11–15, 97–104, 183–188

D

Davis, W.J., 17–25
Deviller, P., 93–96
Dirks, J.F., 43–44

F

Falliers, C.J., 105–113, 193–196, 475–484, 485–486, S1–S3, S39–S49
Feldman, B.R., 17–25
Feldman, C.H., 17–25
Fink, J.N., 285–296
Fox, R.W., 177–181
Furukawa, C.T., 435–444

G

Gopalan A.V., 53–55
Govindan, U.T., 53–55
Govindaraj, M., 53–55
Grebin, B., 17–25
Green, A., 197–214
Gurwitz, D., 31–34

H

Haddad, Z.H., 105–113, 197–214
Halpern, G.M., 251–284

I

Ipacs, J., 11–15

J

Jain, N.K., 241–243
Jennings, B., S51–S60

K

Kaliner, M., S9–S13
Kelly, H.W., 455–466
Kemp J.P., 445–453
Kobayashi, R., 467–474

L

Lakshminarayan, S., 105–113
Lasne, Y., 93–96
Laufer, P., 35–38
Levison, H., 31–34
Lockey, R.F., 177–181
Lubs, M.-L.E., 61–66

M

Mansfield, L.E., 39–42, 133–151, 189–192
Marion, R.J., 97–104, 183–188
Marom, Z., S9–S13
McFadden, E.R., S5–S8
Menendez, R., 411–418, 455–466
Mindorff, C., 31–34
Morris, H.G., S15–S21

N

Nelson, H.S., 189–192

P

Perrin, L.F., 93–96
Pierson, W.E., 435–444
Podleski, E.K., 105–113

R

Reilly, P.A., 31–34

S

Samaan, S.S., 177–181
Schatz, M., 391–409
Schraa, J.C., 43–44
Schur, P.H., 189–192
Seiger, R.S., 391–409
Selcow, J.E., 361–368, 369–375
Shapiro, G.G., 383–389, 435–444
Singh, V., 241–243
Slonim, N.B., 57–59
Sly, R.M., 419–427
Smith, A., 85–91
Sokolova, T.S., 115–131, 245–249
Sroussi, J., 93–96
Stack-Drinkard, G., 215–217
Stevenson, D.D., S31–S38
Studenikin, M.Y., 115–131, 245–249
Szczeklik, A., S23–S39

T

Ting, S., 39–42
Tinkleman, D.G., 331–334, 429–433
Toogood, J.H., S51–S60
Torphy, D.E., 35–38
Townley, R.G., 105–113

U

Upton, R.A., 27–30

V

Voyles, J.B., 411–418

W

Williams, R.L., 27–30

Y

Yarbrough, J., 39–42

Z

Zeiger, R.S., 341–359

Journal of Asthma, 20(6), 489–493 (1983)

SUBJECT INDEX

VOLUME 20

A

Acetaminophen, sensitivity to related to aspirin sensitivity, S39–S49
Acute asthma, changes in body weight and hematocrit values during recovery from , 53–55
Adolescents. *See* Childhood asthma
β-2 Adrenergic agonists. *See* Fenoterol
β-Adrenergic agents, 448–450
  in childhood asthma, 349–352
  and exercise-induced asthma, 387–388
  fenoterol, 31–34
Adrenergic bronchodilators, 445–453
  currently available, 447–448
  See also Bronchodilators
Adverse effects, of immunotherapy, 401
Aerosol inhalers. *See* Nebulizers
Age, IgE levels and, 95–96
β-Agonists, evaluation of efficacy of, 105–113
Airway obstruction, therapy for, 89–91
Alimentary allergy. *See* Food allergies
Allergens
  identification of, 147–148, 251–284
  as precipitants of childhood asthma, 343–344
Allergic asthma, 419–423
Allergies
  and genetics, 61–66
  immunologic procedures in, 133–151
  pediatric, developmental aspects of, 115–131
  role of arachidonic acid metabolites in, S17–S19
  See also Bacterial allergies; Cow's milk allergies; Drug allergies; Food allergies; House dust mite allergy; Pollen allergies
Anaphylaxis, to kiwi fruit, 193–196
Animal-triggered asthma, immunotherapy in, 395–396
Antiasthmatics, evaluation of, 105–113
Anticholinergic agents, in asthma therapy, 372–373
Antihistamines, in asthma therapy, 369–371
Arachidonic acid, influence of aspirin on, S9–S13
Arachidonic acid cascade, pharmacologic influences on, S19–S20
Arachidonic acid metabolites, formation and action of, S16–S17
Ascorbic acid, effect of on pulmonary functions in mild asthma, 39–42
Aspirin
  asthma attacks related to ingestion of, 215–217
  influence of on arachidonic acid, S9–S13
  inhibition of cyclo-oxygenase by, S23–S29
  sensitivity to related to acetaminophen sensitivity, S39–S49
Aspirin-sensitive asthma
  desensitization in, S31–S38
  inhibition of cyclo-oxygenase in, S24–S26
  mechanisms of mucus secretion in, S9–S13
  personal account of, 215–217
Asthma
  gastroesophageal reflux as cause of, 241–243
  pathophysiology of, 419–427
  role of arachidonic acid metabolites in, S17–S19
  See also Acute asthma; Allergic asthma; Animal-triggered asthma; Aspirin-sensitive asthma; Childhood asthma; Chronic asthma; Exercise-induced asthma; Food-related asthma; Infection-induced asthma; Intractable asthma; Intrinsic asthma; Mite induced asthma; Mold-induced asthma; Pollen-induced asthma; Steroid-dependent asthma
Asthma Medication Index (AMI), in evaluation of antiasthmatics, 105–113
Asthma Problem Behavior Checklist (APBC), 97–104
Autoimmune disease, evaluation of, 141–144

B

Bacterial allergies, pediatric, 117–118, 123
Behavioral variables, at residential treatment facility for childhood asthma, 11–15
Behaviors, in childhood asthma, 97–104
Bioavailability, of sustained-release and immediate-release theophylline formulations, 27–30

Note: Numbers with an "S" prefix indicate entries appearing in Supplement 1 of Volume 20.

Body weight, changes in during recovery from acute asthma and chronic bronchitis, 53–55
Breast milk. *See* Childhood asthma, nutrition in; Food allergies
Broken homes, impact of on residential treatment facility for childhood asthma, 12–13
Bronchial asthma, ancillary therapy in, 369–375
Bronchial tolerance, allergen specific, effect of immunotherapy on, 398–399
Bronchodilator therapy, and gastroesophageal refleux, 241–243
Bronchodilators, S26–S27
  adrenergic, 445–453
  fenoteral, 31–34
  metaproterenol, 85–91
  theophylline, 456–457

C

Causes of hypersensitivity pneumonitis, 287–288
Cellular events, in IgE-mediated immediate hypersensitivity reactions, 207–209
Chemical mediators
  in atopic childhood asthma, 247–249
  of pediatric allergies, 121–122
Childhood asthma
  atopic, mechanisms of therapeutic action in, 245–249
  compliance in, 413–415
  compliance and combined drug therapy in emergency room treatment of, 35–38
  exercise-induced, 383–389
  fenoterol in treatment of, 31–34
  immunologically and nonimmunologically mediated, role of cromolyn in, 362–363
  immunotherapy in, 391–409
  initial episode of, 429–433
  long-term maintenance and pharmacologic therapy for, 335–339
  nutrition in, 377–381
  parental perceptions in, 97–104
  in preschoolers, single entity sustained-release theophylline in, 467–474
  residental treatment facility for, 11–15, 17–25
  resistance to therapy in, 435–444
  scope of, 331–334
  special considerations in, 341–359
  systemic and topical corticosteroid therapy in, 474–484
  use of cromolyn in, 361–368
  use of nebulizer in, 183–188
Children
  food allergies in, 254–259
  See also Childhood asthma
Chronic asthma
  theophylline in, 457–459
  See also Childhood asthma
Chronic bronchitis, changes in body weight and hematocrit values during recovery from, 53–55
Classification of asthma, factors in, S5–S8
Clinical-immunologic correlates
  food allergies, 251–284
  hypersensitivity pneumonitis, 285–296
Clinical manifestations of hypersensitivity pneumonitis, 288–289
Clinical presentations, of childhood asthma, 344–345
Clinical trials, in asthma therapy, S51–S60
Clinician, and asthma classification, S5–S8
Compliance
  Asthma Problem Behavior Checklist and, 98–99
  in childhood asthma, 35–38, 183–188
  role of in asthma management, 411–418
Complications, in childhood asthma, 355–356, 441–442
Corticosteroids, in childhood asthma, 353–354, 474–484
Cow's milk allergies, 271–273
Cromolyn
  in childhood asthma, 352–353, 361–368
  in exercise-induced asthma, 387–388
  patient selection for use of, 365–366
Cyclo-oxygenase, inhibition of by aspirin, S23–S29
  See also Arachidonic acid metabolites

D

Dehydration, and asthma, 53–55
Dermatophagoides pteronyssinus. *See* House dust mite allergy
Desensitization, in aspirin-sensitive asthma, S31–S38
Development, of pediatric allergies, 115–131, 254–259
Diagnosis
  of childhood asthma, 429–431
  of food allergies, 252, 271–277
  of hypersensitivity pneumonitis, 293–294
  of pediatric allergies, 122–125
Diagnostic tests, for childhood asthma, 345–346
Disciplinary discharges, from residental treatment facility for childhood asthma, 13–14
Drug allergies
  pediatric, 117, 124–125
  See also Aspirin-sensitive asthma
Dynamic model of asthma, 45–52

E

Emergency room
  reduction in utilization of, 49–52
  treatment of childhood asthma in, 35–38
Edpidemiology, of hypersensitivity pneumonitis, 286
Epinephrine, effect of PTL on effectiveness of, 35–38
Exercise-induced asthma, 383–389
Exotic foods, allergies to, 193–196
Expectorants, in asthma therapy, 371–372

F

Families, effect of childhood asthma on, 100–103

Fenoterol, inhaled and oral, long-term evaluation of, 31–34
Food allergies
  differential diagnosis of, 271–277
  pediatric, 116–117, 123–124, 126, 130
  review and update, 251–284
  to exotic foods, 193–196
Food-related asthma, and nutrition, 377–381

G

Gastroesophageal reflux (GER), as cause of asthma, 241–243, 344
Genetic counseling, for allergy, 66
Genetics and allergies, 61–66, 115–116

H

Hayfever, and childhood asthma, 397
Hematocrit values, changes in during recovery from acute asthma and chronic bronchitis, 53–55
Histologic studies, in hypersensitivity pneumonitis, 292–293
History, of athma classification, S5–S6
HLA complex, 64–66
Home management of asthma, 48, 435–436
Hospitalization
  in childhood asthma, 439–441
  reduction in, 49–52
House dust mite allergy, IgE in, 93–96
Hybridomas, for immunologic testing, 149
Hyperacidity. *See* Gastroesophageal reflux
Hypersensitivity pneumonitis, differential diagnosis of, 285–296
Hypersensitivity reactions, immediate, IgE-mediated, 197–214
Hyposensitization, to house dust, 93–96

I

Immediate hypersensitivity disease, tests for, 144–147
Immediate-release formulations, of theophylline, 27–30
Immune tolerance, in food allergies, 252–253
Immunocologic abnormalities, in pediatric allergies, 118–121
Immunoglobulin E (IgE)
  in atopic childhood asthma, 245–246
  house dust allergies and, 93–96
  mediation of hypersensitivity reactions by, 197–214
Immunoglobulin E (IgE) genetics, 63–64
Immunoglobulin G (IgG), subclasses of in asthmatic patients, 189–192
Immunoglobulins, in pediatric allergies, 118–121
Immunologic components
  cellular mediated, tests for, 137–141
  humorally mediated, tests for, 133–137
Immunologic parameters, effect of immunotherapy on, 399–401
Immunologic procedures, clinical, in allergies, 133–151
Immunological tests, in food allergies, 264–268
Immunopathogenic mechanisms, in hypersensitivity pneumonitis, 286–287
Immunotherapy
  adverse effects of, 401
  in childhood asthma, 246–247, 391–409
Infants. *See* Childhood asthma
Infection-induced asthma, immunotherapy in, 396
Inflammation, control of 49
Initial episode, of childhood asthma, 429–433
Intractable asthma definition of, 18
  See also Childhood asthma
Intrinsic asthma, 423–425
  See also Exercise-induced asthma
Iodides, in asthma therapy, 371–372

K

Kiwi fruit, allergy to, 193–196

L

Laboratory features of hypersensitivity pneumonitis, 289
Legal disability, and pulmonary function tests, 57–59
Long-term maintenance, in childhood asthma, 335–339
Low-dose therapy, metaproterenol-theophylline, 85–91
Lung injuries, inhalation, tests for, 57–59
Lipoxegenase
  and mucus production in aspirin-sensitive asthma, S9–S13
See also Arachidonic acid metabolites

M

Manifestations of food allergies, 259–264
Mediator release
  in allergic asthma, 419–422
  control of, 205–207
  mechanisms of, 197–205
Metabolites, of arachidonic acid, S15–S21
Metaproterenol, use of in combination with theophylline, 85–91
Minorities, in residential treatment facility for childhood asthma, 13
Mite-induced asthma, immunotherapy in, 392–395
Mold-induced asthma, immunotherapy in, 396
Molecular pharmacology, of theophylline, 456
Monoclonal antibodies, for immunologic testing, 149
Mucolytic agents, in asthma therapy, 371–372
Mucosal edema, in asthma, S9–S13, S15–S21
Mucus, mechanisms of secretion of in aspirin-sensitive asthma, S9–S13

N

Nasal polyposis, and aspirin sensitivity, 215–216, S47–S48
National Jewish Hospital/National Asthma Center, behavioral studies in, 11–15, 97–103
Nebulizers, in childhood asthma, 183–188, 354
Nonallergic asthma. *See* Intrinsic asthma
Nonsteroidal anti-inflammatory drugs (NSAIDs). *See* Acetaminophen; Aspirin
Nutrition, and food-related asthma, 377–381

O

Oxtriphylline, sustained release, use of for asthma therapy, 177–181

P

Pathophysiology, of asthma, 45–48, 341–342, 419–427
Patient reports, of asthma symptoms, 43–44
Patient selection, for immunotherapy, 402–403
Pediatric astma. *See* Childhood asthma
Personal account, of drug-related asthma, 215–217
Pharmacologic influences, on arachidonic acid cascade, S19–S20
Pharmacologic therapy, long-term, in childhood asthma, 335–339
Pharmacological mediators, of immediate hypersensitivity reactions, 205–207
Pharmakokinetics, of theophylline, 459
Plasma theophylline level (PTL), effect of on epinephrine effectiveness, 35–38
Pollen allergies, pediatric, 117, 123, 126–127
Pollen-induced asthma, immunotherapy in 392
Prausnitz-Kustner passive transfer test. *See* Immunological tests
Precipitation test. *See* Immunological tests
Predisposing factors to hypersensitivity pneumonitis, 285–286
Preschoolers. *See* Childhood asthma, in preschoolers
Prevention of food allergies, 277–278
Prostaglandins, and mucus production in aspirin-sensitive asthma, S9–S13
Pulmonary function
  in mild asthma, effect of ascorbic acid on, 39–42
  monitoring of, 48–49
  in pulmonary pneumonitis, 290–292
  tests for, 58–59

Q

Quality of life, in long-term therapy for childhood asthma, 336

R

Radio-Allergo-Sorbent Test (RAST), predictive value of, for house dust sensitization, 93–96
Radiography, of hypersensitivity pneumonitis, 289–290
Reaginic antibody. *See* Immunoglobulin E (IgE); Immunoglobulin G (IgG); Immunoglobulins
Regional residential treatment facility for childhood asthma, 17–25
Rehospitalization, and patient mislabeling of asthma symptoms, 43–44
Remission, in residential treatment facility for childhood asthma, 11–15
Research needs, in childhood asthma, 336–337
Residential treatment facility for childhood asthma, 11–15, 17–25

S

St. Mary's Hospital for Children, 17–25
Secretion of mucus, in aspirin-sensitive asthma, S9–S13
Sensitization, in allergic asthma, 422–423
Sex, IgE levels and, 94–95
Side effects
  of adrenergic bronchodilators, 450–451
  of metaproterenol-theophylline therapy, 88–89, 90
Social variables, at residential treatment facility for childhood asthma, 11–15
Steroid-dependent asthma, immunotherapy in, 396
Steroids
  in asthma treatment, S51–S60
  evaluation of efficacy of, 105–113
Structure-function relationships, of adrenergic bronchodilators, 446–447
Sustained-release formulations
  of oxtriphylline, use of for asthma therapy, 177–181
  of theophylline, 27–30, 459–463
  in preschool children, 467–474
Sympathomimetics. *See* Metaproterenol
Symptoms of asthma, patient reports of 43–44
Systemic therapy, coricosteroid, 474–484

T

Theophylline, 455–466
  bioavailability of sustained and immediate-release formulations of, 27–30
  in childhood asthma, 348–349
  choline salt of. *See* Oxtriphylline
  effect of therapeutic doses of on epinephrine effectiveness, 35–38
  and exercise-induced asthma, 387–388
  use of in combination with metaproterenol, 85–91
Therapeutic efficacy, of asthma drugs, 105–113
Therapy
  clinical trials for, S51–S60
  See also Bronchodilator therapy; Immunotherapy;

Pharmacologic therapy; Topical therapy
Topical therapy, corticosteroid, 474–484
Training, of children, in nebulizer use, 183–188
Treatment program, for residential treatment facility for childhood asthma, 20–23
Treatment schedules, for corticosteroid therapy in childhood asthma, 479–482
Treatment
of childhood asthma, 346–355
of pediatric allergies, 122–125

V

Viral infections, as precipitant of childhood asthma, 342–343
Vitamin C. *See* Ascorbic acid

X

Xanthines, evaluation of efficacy of, 105–113